Aceclidine Eye Drop Dosing for Presbyopia Without Distance Vision Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for presbyopia, such as miotic agents, induce transient myopia reducing distance vision and cause significant side effects like blurred vision, pain, redness, and risk of retinal detachment, necessitating a non-invasive and convenient solution with minimal side effects.
Innovation Solution
Administering a composition comprising 0.1% to 3.5% w/v of aceclidine multiple times within 24 hours, preferably within 1 hour of initial administration, combined with surfactants and viscosity agents to enhance duration and efficacy, while minimizing distance vision reduction and side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If miotic agents are used to treat presbyopia, then near vision is improved, but distance vision is reduced and side effects occur
Solution Approach 1:
The patent changes the pharmacological parameters by using aceclidine hydrochloride at specifically controlled concentrations (0.01% to 5.0% w/v) and administering it multiple times within 24 hours, which modifies the drug's effect profile to improve near vision while minimizing distance vision reduction and side effects compared to conventional single-dose miotic agents
Solution Approach 2:
The patent implements periodic administration of the miotic agent by requiring multiple doses within 24 hours, which maintains sustained near vision improvement while allowing the eye to recover between doses, thereby reducing cumulative side effects and distance vision impairment
2Measurement precision
If miotic agents are administered at high concentrations, then near vision improvement is enhanced, but side effects like pain, redness, and retinal detachment risk increase
Solution Approach 1:
The patent optimizes the concentration parameter by establishing a specific range (0.01% to 5.0% w/v) for aceclidine hydrochloride, which balances near vision improvement with safety, avoiding the excessive concentrations that cause severe side effects while maintaining therapeutic efficacy
Solution Approach 2:
The patent ensures continuous near vision improvement through multiple administrations within 24 hours, which maintains sustained therapeutic effect while distributing the total dose over time, thereby reducing peak concentration-related toxicity and severe side effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method improves near vision acuity and duration of effect, maintains distance vision, reduces redness and pain, and prevents retinal detachment, with enhanced depth perception and reduced rebound hyperemia.
Implementation Method 1
improving near vision acuity and depth of focus... improves depth perception
Implementation Method 2
combined with surfactants and viscosity agents to enhance duration and efficacy
Data Source
AI summary
The present invention is directed to treating presbyopia, irregular astigmatism, and/or refractive error, comprising administering a composition comprising from about 0.1% to about 3.5% w/v of aceclidine to a subject in need thereof, wherein administration occurs 2 or more times within 24 hours of initial administration.